Time to Entry for Cancer New Medicines: From European Union–wide Marketing Authorization to Patients Access in Belgium, Estonia, Scotland, and Sweden

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.01.003
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Php57 - European Conditional Marketing Authorization – Does Early Marketing Authorization Translate Into Early Reimbursement and Patient Access?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Access to Medicines and European Market Integration

SSRN Electronic Journal
2016English

From Entry to Access

2007English

The European Medicines Agency Facilitates Access to Medicines in Low- And Middle-Income Countries

Expert Review of Clinical Pharmacology
MedicineToxicologyPharmaceuticsPharmacology
2020English

Authorization Systems for Use of Unlicensed Medicines in European Countries

Iryo To Shakai
2008English

Access to Cross-Border Health Care Services for Patients With Rare Diseases in the European Union

Orphan Drugs: Research and Reviews
Drug DiscoveryPharmaceutical Science
2014English

Php301 - The Time Is Now for European Hta: How Will the Evolution of European Hta Impact Access to Innovative Medicines?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Access to Information in Belgium

2018English

Proposals on Faster NHS Access to New Medicines

Prescriber
Pharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy